Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Mehta is a 2018 Seattle Met Top Doctor Award winner. He enjoys working with patients and family members. There are a wide variety of treatment options available for nearly every patient, so it is important to spend as much time as is needed in order to weight the benefits and risks to any particular approach. He feels that it is important that communication is open and honest. The goals of treatment, whether it is going for cure or maximizing quality of life should be openly discussed and re-discussed as the need arises.  For more about Dr.

Prophylactic Cranial Irradiation for Limited Stage Small Cell Lung Cancer
Author
Vivek Mehta, MD., GRACE Faculty
Radiation to the brain is a component of our treatment of limited stage small cell lung cancer, even with no evidence of cancer there. Dr. Vivek Mehta, radiation oncologist, reviews why we would do such a thing.

 

Transcript

Small cell cancer is a type of lung cancer that presents in basically two formats. One format is that the disease is actually limited to what classically, in the old days, radiation oncologists called “the box,” meaning that it was limited to the chest. When we talk about limited stage small cell carcinoma, we’re talking, potentially, about a disease that is very responsive to treatment, and sometimes can be cured. When we cure those patients, with a combination of chemotherapy and radiation for limited stage small cell carcinoma, we often look to see if the cancer has spread to the brain. We do this by getting MRI studies of the brain; if there’s no evidence of disease in the brain, and the treatment has effectively worked in the chest at eradicating the disease, we all are very happy.

Unfortunately, if you follow these patients over time, they have a very high chance of having the cancer come back in the brain — the brain is thought to be a sanctuary site, meaning that it doesn’t get the treatment from the chemotherapy that the rest of the body gets, so if any cells have snuck up there, they sometimes can grow without the treatment that’s been delivered so far.

One of the things that we’ve done in the past is deliver a very low dose of radiation to the whole brain, as a prophylactic treatment — that’s often called PCI, or prophylactic cranial irradiation. We offer this routinely to patients with limited stage disease because the studies have demonstrated that if you give prophylactic treatment, you reduce the chances of the cancer coming back in the brain, and if you reduce the chances of the cancer coming back in the brain, you presumably reduce the chances of all those symptoms that cancer in the brain can cause.

We often talk about the brain as being the “high rent district.” If we can keep cancer out of the brain, we can keep people much more functional, not have the risks of strokes, and mental problems, and seizures that cancer in the brain can cause, so we often give prophylactic cranial irradiation.

Prophylactic cranial irradiation is a little bit different than whole brain radiation: the doses that you give each day are lower, the dose that you give overall is lower, because you’re treating disease that you can’t see, you’re not treating the disease that is actually already there — hence the word prophylactic cranial irradiation.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated. 
Image
2024-25 patient perspectives header
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial.  We want to hear from you!
Image
Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón
Video
¡El vídeo completo bajo demanda está disponible para verlo!

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on
EGFR
By happybluesun on